1. [Anti-inflammatory drugs and community-acquired pneumonia].
- Author
-
Dirou S and Voiriot G
- Subjects
- Adult, Animals, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Antipyretics pharmacology, Antipyretics therapeutic use, Case-Control Studies, Child, Cyclooxygenase 2 Inhibitors pharmacology, Cyclooxygenase 2 Inhibitors therapeutic use, Empyema, Pleural etiology, Fever drug therapy, Fever etiology, Humans, Inflammation drug therapy, Inflammation physiopathology, Mice, Neutrophil Infiltration drug effects, Practice Guidelines as Topic, Pulmonary Gas Exchange drug effects, Risk, Self Medication, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Antipyretics adverse effects, Community-Acquired Infections complications, Cyclooxygenase 2 Inhibitors adverse effects, Empyema, Pleural chemically induced, Pneumonia, Bacterial complications
- Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used in ambulatory medicine for their analgesic and antipyretic properties and are often used as self-medication. Their use in community-acquired pneumonia is associated with an increased risk of loco-regional complications, especially pleural empyema. Appropriate therapeutic care and hospital admissions are often delayed because of initial improvement of symptoms with NSAIDs. Despite worrying observational data, a causal link remains to be established. Currently, there is no recommendation cautioning against the use of NSAIDs in the management of community-acquired pneumonia., (Copyright © 2015 SPLF. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF